Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Pratique neurologique - FMC
Volume 3, n° 2
pages 111-118 (avril 2012)
Doi : 10.1016/j.praneu.2012.01.012
Immunité et maladies neuro-musculaires
Anti-CD20 et maladies neuromusculaires : quelles indications et quel usage ?
Anti-CD20 and neuromuscular disease: Indications and use
 

E. Delmont
Centre de référence maladies neuromusculaires et la SLA, hôpital Archet-1, route Saint-Antoine-de-Ginestière, 06200 Nice cedex 3, France 


Mots clés : Rituximab, Maladies neuromusculaires, Neuropathie anti-MAG, Neuropathie motrice multifocale, Myasthénie, Myopathie

OutlineMasquer le plan
Polyneuropathies avec anticorps anti-myelin associated glycoprotein
Neuropathie motrice multifocale avec blocs de conduction
Polyradiculonévrite inflammatoire démyélinisante chronique
Myasthénie auto-immune
Myopathies auto-immunes
Effets secondaires et tolérance du rituximab
Questions en suspens et conclusion
Déclaration d’intérêts
1  FORCE. Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis. Clinical trials.gov: NCT00774462. click Here .
2  RIM study: phase II trial. Rituximab for the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) (clinical trials.gov NCT 00106184). click Here .


© 2012  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline